Morgan Stanley analyst Terence Flynn maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Biontech konnte im dritten Quartal Umsatz genauso wie Nettogewinn steigern. Getrieben wird der Umsatz von angepassten ...

Nach steigenden Umsätzen und Gewinnen dämpft BioNTech-Chef Uğur Şahin die Erwartungen für 2024. Milliardenausgaben für die ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $127.53, ...

German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

In a report released yesterday, Chris Shibutani from Goldman Sachs upgraded BioNTech SE (BNTX – Research Report) to a Buy, with a price ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Fintel reports that on November 8, 2024, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt () ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...